Galacto-oligosaccharide for Acute Graft-versus-Host Disease
This trial is testing whether a dietary supplement can help prevent a complication from stem cell transplant.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are any new participants being accepted for this research endeavor?
"Data accessible on clinicaltrials.gov affirms that this is an ongoing endeavour, which began being advertised on the 22nd of January 2021 and was most recently refreshed on the 22nd of September 2022."
What set of goals is this medical trial striving to achieve?
"Within a month-long timespan, this study aims to quantify the prevalence of grade II-IV acute GVHD at day 100. Secondary objectives include measuring acute GI toxicities through Day 30 as assessed by CTCAE v5., self-reported evaluations of different symptoms on a 5 point ordinal scale per PRO-CTCAE and chronic GVHD scoring following NIH consensus criteria at both 365 days and 730 days post treatment."
Might I be qualified to join this research endeavor?
"This medical trial has a capacity of 128 individuals aged 18 to 80 with acute GVHD. Additional criteria for enrollment include being prepared to receive allogenic HCT, and having a Karnofsky Performance Status greater than 70 points."
How many individuals have been enlisted in this clinical trial?
"Affirmative, according to clinicaltrials.gov this trial is still recruiting volunteers and has been since January 22nd 2021. The last update was on September 22nd 2022 with the goal of enrolling 128 patients from one site."
Does this research endeavor accept enrollees under the age of eighty?
"Those interested in participating must be aged 18 to 80; there are 1 additional clinical trial available for minors and two more studies specifically designed for senior citizens."